Prothena reported -43209000 in Operating Profit for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Profit Change
Acadia Pharmaceuticals ACAD:US $ -33.65M 79.36M
Agios Pharmaceuticals AGIO:US $ -94.94M 3.5M
Akebia Therapeutics AKBA:US $ 52.5M 111M
ALKERMES ALKS:US -34457000 7.87M
Alnylam Pharmaceuticals ALNY:US $ -191.69M 44.95M
Amgen AMGN:US $ 2176M 324M
Biogen BIIB:US $ -59.1M 669.8M
Biomarin Pharmaceutical BMRN:US $ 39.15M 98.18M
Bluebird Bio BLUE:US $ -107.4M 12.95M
Exelixis EXEL:US $ 83.71M 0.46M
Intercept Pharmaceuticals ICPT:US $ -13.36M 3.09M
Intra Cellular Therapies ITCI:US $ -87.92M 15.26M
IONIS PHARMACEUT IONS:US $ -85.51M 28.01M
Macrogenics MGNX:US $ -41808000 24.83M
Nektar Therapeutics NKTR:US $ -152.84M 36.28M
Neurocrine Biosciences NBIX:US $ -15.3M 18.4M
Prothena PRTA:US -43209000 5.26M
Regeneron Pharmaceuticals REGN:US $ 1109.9M 148.6M
Seattle Genetics SGEN:US $ -133.11M 0.06M
Ultragenyx Pharmaceutical RARE:US $ -141.59M 4.96M
Vertex Pharmaceuticals VRTX:US $ 1106.3M 65.4M
Vital Therapies VTL:US $ -20.61M 0.82M
Xoma XOMA:US $ -4767000 2.7M
YTE INCY:US $ 254.43M 137.89M